HOME >> MEDICINE >> NEWS
First US SARS vaccine trial opens at NIH

Powerful research tools that speed up vaccine development have led to the start today of human tests for a preventive vaccine against the respiratory disease SARS. The disease killed hundreds of people around the world before it was brought under control in 2003 with aggressive conventional public health measures.

Researchers at the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), will conduct the trials. The experimental vaccine against SARS, or severe acute respiratory syndrome, will be tested on 10 healthy volunteers at the NIH Clinical Center in Bethesda, MD. The clinic will do periodic follow-up exams on each volunteer for 32 weeks.

"This experimental vaccine is an outstanding achievement by NIAID researchers," said Health and Human Services Secretary Tommy G. Thompson. "It is a model for research that could greatly shorten the time needed to create vaccines to be tested against other diseases."

"The Vaccine Research Center, a cutting-edge facility established here at NIH just five years ago, encompasses the entire spectrum of vaccine development from basic research to clinical testing," says NIH Director Elias A. Zerhouni, M.D. "This is why our team at NIAID has been able to develop this vaccine at an unprecedented pace, using technological discoveries that were not available just a few short years ago."

The primary goal of the study is to determine if the experimental vaccine is safe in people. A secondary goal is to assess how well the vaccine stimulates the immune system to produce antibodies and cellular immunity, in this case, focusing on the SARS spike protein. The spike protein protrudes from the virus' outer envelope and helps it bind to cells it infects.

SARS was spotted first in China in November 2002. The virus sickened 8,096 and killed 774 worldwide by July 2003, according to the World Health Organization (WHO). SARS was
'"/>

Contact: Linda Joy
ljoy@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
13-Dec-2004


Page: 1 2 3

Related medicine news :

1. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
2. First UK cases of previously rare disease reported in gay men
3. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
4. Mayo Clinic researchers create obedient virus; First step to use measles virus against cancer
5. First US kidney cancer vaccine trial underway at Columbia
6. First new treatment for alcoholism in ten years, now available Campral(R) (acamprosate calcium)
7. First blood test to diagnose paralyzing, blinding disease
8. First-ever safety study of medical cannabis use in Canada launched
9. First solid evidence that the study of music promotes intellectual development
10. First medical test on CD gets good results
11. First proof that cutting Rx drugs due to cost harms health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: First SARS vaccine trial opens NIH

(Date:4/24/2015)... April 24, 2015 Ryadon is a ... range of capabilities and services to complement any custom ... Quantity Discount Program will be offered on all heavy ... Order 4-19: Receive 10% discount - Order 20+: Receive ... the Drawer Slides Products, Furniture ...
(Date:4/24/2015)... TX (PRWEB) April 24, 2015 The Fastest ... Long, after their great success of the Xtreme Fat Loss ... industry. The fat loss blueprint that claims to help ... the attention of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. ... shows that the creators spent years researching and experimenting with ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 The 1975 ... toured almost constantly across the globe to theaters, festivals and ... in Manchester, they’ve partnered with their label, Dirty Hit Records, ... Teaming up with the newly launched Cadence & Cause ... their debut LP on vinyl and a signed photo card. ...
(Date:4/24/2015)... 24, 2015 The first step to ... mind. , For meditation and yoga teacher Stine Koppernæs, ... been invaluable tools that allow her to experience more ... has been a teacher since 2006, and through the ... state of being. , “I love sharing this way ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Carinsurancequotesinfo.com has ... blog post explaining how to qualify for auto ... parents can qualify for auto insurance online, without having ... post explains that single parents can reduce their auto ... released article and properly explained. , Clients can ...
Breaking Medicine News(10 mins):Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Internationally Recognized British Indie Rock Outfit The 1975 Partner with Cadence & Cause to Provide Clean Drinking Water to Those in Need 2Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2
(Date:4/24/2015)... - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), ... marijuana products and a licensed producer ("LP") to cultivate ... Canada ) ("MMPR"), is pleased to announce ... closed the transaction announced on March 11, 2015 with ... Transfer") a total of 20,156,790 common shares of T-Bird ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
(Date:4/23/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ... Revenue for the quarter was $422.5 million, a 6 ... 2014 (a 13 percent increase on a constant currency ... 1 percent compared to the quarter ended March 31, ... $0.64, an increase of 2 percent compared to the ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
Cached News: